NCT03043313 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 114
- units
- Participants
- groups
- description
- Non-randomized cohort. Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Trastuzumab 8 mg/kg by IV infusion on Day 1 of Cycle 1 and 6 mg/kg on Day 1 of each subsequent cycle until PD, death, withdrawal of consent, study closure, or alternative therapy.
- id
- BG000
- title
- Tucatinib+Trastuzumab (Cohort A)
- description
- Randomized cohort. Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Trastuzumab 8 mg/kg by IV infusion on Day 1 of Cycle 1 and 6 mg/kg on Day 1 of each subsequent cycle until PD, death, withdrawal of consent, study closure, or alternative therapy.
- id
- BG001
- title
- Tucatinib+Trastuzumab (Cohort B)
- description
- Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Participants who did not respond to monotherapy were given the option to receive tucatinib and trastuzumab until PD, death, withdrawal of consent, study closure, or alternative therapy based on radiographic progression (as determined by investigator assessment using RECIST v1.1), or if they had not achieved a PR or CR by the week 12 assessment.
- id
- BG002
- title
- Tucatinib Monotherapy (Cohort C)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 24
- upper Limit
- 71
- value
- 52
- group Id
- BG001
- lower Limit
- 31
- upper Limit
- 77
- value
- 57
- group Id
- BG002
- lower Limit
- 29
- upper Limit
- 75
- value
- 59.5
- group Id
- BG003
- lower Limit
- 24
- upper Limit
- 77
- value
- 56
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 48
- title
- Female
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 66
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 89
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 21
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 6
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 88
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 67
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 44
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Grade 2
- description
- ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed less than (\<)50 percent (%) of the time; 3= In bed \>50% of the time; 4=100% bedridden; 5=Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 85
- title
- North America
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 29
- title
- Europe
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Full Analysis Set included all participants who were enrolled and received any amount of study treatment and had human epidermal growth factor receptor 2+ (HER2+) tumors as defined by one or more protocol required local tests.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 114
- units
- Participants
- groups
- description
- Non-randomized cohort. Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Trastuzumab 8 mg/kg by IV infusion on Day 1 of Cycle 1 and 6 mg/kg on Day 1 of each subsequent cycle until PD, death, withdrawal of consent, study closure, or alternative therapy.
- id
- BG000
- title
- Tucatinib+Trastuzumab (Cohort A)
- description
- Randomized cohort. Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Trastuzumab 8 mg/kg by IV infusion on Day 1 of Cycle 1 and 6 mg/kg on Day 1 of each subsequent cycle until PD, death, withdrawal of consent, study closure, or alternative therapy.
- id
- BG001
- title
- Tucatinib+Trastuzumab (Cohort B)
- description
- Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Participants who did not respond to monotherapy were given the option to receive tucatinib and trastuzumab until PD, death, withdrawal of consent, study closure, or alternative therapy based on radiographic progression (as determined by investigator assessment using RECIST v1.1), or if they had not achieved a PR or CR by the week 12 assessment.
- id
- BG002
- title
- Tucatinib Monotherapy (Cohort C)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 24
- upper Limit
- 71
- value
- 52
- group Id
- BG001
- lower Limit
- 31
- upper Limit
- 77
- value
- 57
- group Id
- BG002
- lower Limit
- 29
- upper Limit
- 75
- value
- 59.5
- group Id
- BG003
- lower Limit
- 24
- upper Limit
- 77
- value
- 56
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 48
- title
- Female
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 66
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 89
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 21
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 6
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 88
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 67
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 44
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Grade 2
- description
- ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed less than (\<)50 percent (%) of the time; 3= In bed \>50% of the time; 4=100% bedridden; 5=Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 85
- title
- North America
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 29
- title
- Europe
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Full Analysis Set included all participants who were enrolled and received any amount of study treatment and had human epidermal growth factor receptor 2+ (HER2+) tumors as defined by one or more protocol required local tests.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle